Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
19 avr. 2024 16h30 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
06 mars 2024 09h00 HE
|
BIOXYTRAN, INC.
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
16 févr. 2024 08h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...
Hepion Pharmaceuticals to Present at NASH-TAG 2024
03 janv. 2024 17h15 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
07 déc. 2023 08h00 HE
|
Hepion Pharmaceuticals, Inc.
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account...
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
30 nov. 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
17 nov. 2023 08h00 HE
|
Serina Therapeutics, Inc.
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a...
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
16 nov. 2023 08h30 HE
|
Incannex Healthcare
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia...
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
24 oct. 2023 08h45 HE
|
BIOXYTRAN, INC.
Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
28 août 2023 08h00 HE
|
Innovation Pharmaceuticals Inc
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in...